Emerging therapeutic approaches in renal cell carcinoma.

Abstract

In the past decade, targeted therapy with VEGF and mTOR inhibition has significantly improved the outcome of renal cell carcinoma. However, the management of metastatic renal cell carcinoma still remains challenging as most patients eventually progress on targeted therapy, and long-term survivors are still relatively uncommon. There has recently been a resurgence of interest in cancer immunotherapy with the development of checkpoint inhibitors. Here we discuss the best methods to optimize the current standard of care with targeted therapy, and describe select emerging targeted therapies and immunotherapies with anti programmed death-1 pathway inhibitors in the management of metastatic renal cell carcinoma.

• Authors: Hiral Parekh, Brian I Rini
• Journal: Expert review of anticancer therapy (Expert Rev Anticancer Ther) Vol. 15 Issue 11 Pg. 1305-14 ( 2015) ISSN: 1744-8328 [Electronic] England
• PMID: 26376584 (Publication Type: Journal Article, Review)

Chemical References

• PDCD1 protein, human
• Programmed Cell Death 1 Receptor

Topics

• Carcinoma, Renal Cell (drug therapy, pathology)
• Disease Progression
• Humans
• Immunotherapy (methods)
• Kidney Neoplasms (drug therapy, pathology)
• Molecular Targeted Therapy
• Neoplasm Metastasis
• Programmed Cell Death 1 Receptor (antagonists & inhibitors)